University of Pennsylvania - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Region:North America

Author(s):

Product Code:GDPH67297D

Download Sample Report download
Buy the Full ReportStarting from $250
Published on

October 2018

Total pages

120

Table of Content

Download Sample Report download
Buy the Full ReportStarting from $250

About the Report

About the Report

Summary

University of Pennsylvania (UOP) is an educational university that provides distance learning facilities for professional courses. The university offers courses such as art and archaeology, accounting, biochemistry, bioengineering, biomedical graduate studies, city and regional planning, criminology, fine arts, finance, operations and information management, telecommunications, theatre arts, and visual studies, among others. Its schools include school of arts and sciences, school of dental medicine, school of design, school of engineering and applied science, school of medicine and school of nursing. The university also offers arts, athletics, healthcare, libraries, online learning and global service facilities. UOP is headquartered in Philadelphia, Pennsylvania, the US.

University of Pennsylvania-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

Products

Products

University of Pennsylvania, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Table of Contents

Table of Contents

Table of Contents

Table of Contents 3

List of Tables 6

List of Figures 7

University of Pennsylvania, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8

University of Pennsylvania, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 9

University of Pennsylvania, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10

University of Pennsylvania, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 11

University of Pennsylvania, Medical Devices Deals, 2012 to YTD 2018 13

University of Pennsylvania, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 14

University of Pennsylvania, Pharmaceuticals & Healthcare, Deal Details 18

Venture Financing 18

Carisma Therapeutics Raises USD53 Million in Series A Financing 18

Tmunity Therapeutics Raises Additional USD35 Million in Series A Venture Financing 20

Tmunity Therapeutics Raises USD100 Million in Series A Venture Financing 22

Partnerships 24

Amicus Therapeutics Enters into Research and Development Agreement with Perelman School of Medicine at the University of Pennsylvania 24

BioRestorative Therapies Enters into Research Agreement with University of Pennsylvania 25

Aevitas Therapeutics Enters into Research Agreement with University of Pennsylvania 26

Ophthotech and University of Pennsylvania Enter into Agreement 27

Johnson & Johnson Innovation and Janssen Pharma Enter into Research Partnership with University of Pennsylvania 28

JW Pharma Enters into Agreement with University of Pennsylvania 29

Incyte Enters into Research Agreement with Abramson Cancer Center 30

Tempus Health Enters into Agreement with Penn Medicine 31

Liquid Biotech Enters into Research Agreement with University of Pennsylvania 32

Celgene Enters into Co-Development Agreement with Abramson Cancer Center 33

Bluepen Biomarkers Enters into Agreement with University of Pennsylvania 34

Biogen Enters into Co-Development Agreement with University of Pennsylvania 35

Seres Therapeutics Enters into Agreement with University of Pennsylvania 36

Audentes Therapeutics Amends Co-Development with University of Pennsylvania 37

Genisphere Enters into Research Agreement with University of Pennsylvania 38

NeuroVive Pharma Enters into Research Agreement with University of Pennsylvania 39

Johnson & Johnson Consumer Enters into Research Agreement with University of Pennsylvania 40

Janssen Pharma Enters into Agreement with University of Pennsylvania 41

Lightlake Therapeutics Enters into Agreement with University of Pennsylvania 42

Epic Sciences Partners with Abramson Cancer Center 43

BioRestorative Therapies Enters into Research Agreement with University of Pennsylvania 44

PTC Therapeutics Enters into Agreement with University of Pennsylvania 45

CCFA Enters into Research Agreement with Penn Med and Nestle Health Science 46

Dimension Therapeutics Amends Research Agreement with University of Pennsylvania 47

Genzyme Enters into Co-Development Agreement with University of Florida and University of Pennsylvania 48

PolyMedix Enters Into Co-Development Agreement With University of Pennsylvania 49

Licensing Agreements 50

Precision BioSciences Enters into Licensing Agreement with University of Pennsylvania 50

Ophthotech Enters into Licensing Agreement with University of Florida Research Foundation and the University of Pennsylvania 51

ImmunoRestoration Enters into Licensing Agreement with University of Pennsylvania 52

Arrakis Therapeutics Enters into Licensing Agreement with University of Pennsylvania 53

Expres2ion Biotech Enters into Licensing Agreement with University of Pennsylvania 54

Dimension Therapeutics Enters into Licensing Agreement with Perelman School of Medicine at the University of Pennsylvania 55

Kythera Biopharma Enters into Licensing Agreement with University of Pennsylvania 56

Spark Therapeutics Enters into Licensing Agreement with University of Pennsylvania for Proviral Plasmids 57

Regenxbio Enters into Licensing Agreement with University of Pennsylvania and University of Minnesota 58

Advaxis and University of Pennsylvania Restructure Their Exclusive License Agreement 59

Cetazam Therapeutics Enters into Licensing Agreement with Perelman School of Medicine 60

Amyndas Pharma Enters into Licensing Agreement with University of Pennsylvania 61

Spark Therapeutics Amends Licensing Agreement with University of Pennsylvania 62

Novartis Enters Into Licensing Agreement With University of Pennsylvania For All CARs 63

ImmunoCellular Therapeutics Enters Into Licensing Agreement With University of Pennsylvania For Dendritic-Cell Production Technology 65

Agios Pharma Enters Into Licensing Agreement With University of Pennsylvania 66

Equity Offering 67

Tmunity Therapeutics Raises USD10 Million in Equity Financing 67

Asset Transactions 68

University Of Pennsylvania Sells Portion Of Royalty Interest In Juxtapid For USD 55 Million 68

Acquisition 69

University of Pennsylvania Health System To Acquire Chester County Hospital 69

University of Pennsylvania-Key Competitors 70

University of Pennsylvania-Key Employees 71

University of Pennsylvania-Locations And Subsidiaries 72

Head Office 72

Other Locations & Subsidiaries 72

Recent Developments 73

Government and Public Interest 73

Oct 03, 2018: Patient death following CAR-T therapy highlights serious manufacturing issues 73

Sep 24, 2018: National Institutes of Health names CHOP, Penn an undiagnosed diseases network site 75

Aug 24, 2018: Drs. Kellie Smith, Jeffrey Thompson, and Edwin Yau receive prestigious LUNGevity 2018 Career Development Awards 76

Aug 10, 2018: Cancer cells release biological 'drones' to fight immune system, research 77

Jul 30, 2018: Diabetes Drugs Act as Powerful Curb for Immune Cells in Controlling Disease-causing Inflammation 78

Jul 18, 2018: St. Baldrick's foundation announces USD 19.1 million in grants to fund lifesaving childhood cancer research 79

Jun 28, 2018: Kidney Disease Patients' Experience Of Care And Illness Can Take A Large Emotional Toll 80

May 23, 2018: Foundation for Anesthesia Education and Research Awards USD 1.4 million in Grants 81

May 15, 2018: Penn Study Finds that Different Diseases Elicit Distinct Sets of Exhausted T Cells 84

Apr 25, 2018: Penn Bioinformatics Researcher Receives Big-Data Grant from the Chan Zuckerberg Initiative 85

Apr 24, 2018: Bacteria boost antifungal drug resistance in severe childhood tooth decay 86

Apr 23, 2018: New Cell Therapy Aids Heart Recovery Without Implanting Cells 88

Jan 30, 2018: New study shows severe toxicity with high-dose AAV9-based gene therapy in animal models 90

Dec 11, 2017: CAR T, Immunotherapy Bring New Hope for Multiple Myeloma Patients 91

Sep 27, 2017: Melanoma Cells Rewire Their Signaling Pathways to Resist Drug Treatment 93

Sep 26, 2017: PCORI Board approves USD 8.6 million for study on treatment options for psoriasis and USD 2.75 million for research on atrial fibrillation 94

Jul 18, 2017: New Combination of Anti-obesity Drugs may have Beneficial Effects 95

Jun 26, 2017: CRI Announces USD 1 Million Technology Impact Award Recipient 96

May 18, 2017: Researchers connect brain blood vessel lesions to intestinal bacteria 97

Feb 24, 2017: Penn Vet Team Identifies New Therapeutic Targets for the Tropical Disease Leishmaniasis 99

Product News 101

Sep 12, 2018: Regrowing dental tissue with stem cells from baby teeth 101

Aug 20, 2018: NCI-led research team develops predictor for immunotherapy response in melanoma 103

Mar 28, 2018: Progress in Quest to Develop a Human Memory Prosthesis 104

Mar 05, 2018: New Gene Therapy Corrects a Form of Inherited Macular Degeneration in Canine Model 106

Feb 20, 2018: Penn Engineers Test Drug Transfer Using Placenta-on-a-Chip 108

Feb 12, 2018: Penn Chemists Develop Motion Capture-like Technology for Tracking Protein Shape 110

Other Significant Developments 112

Sep 25, 2018: Susan G. Komen announces USD 26 million investment in new research to find solutions for aggressive and metastatic breast cancers, and to help communities most at risk 112

Aug 15, 2018: 'BOOST-3' Trial Seeks to Improve Outcomes After Severe Traumatic Brain Injury 114

Jul 09, 2018: Penn announces publication of clinically relevant genome editing in primates using precision's ARCUS platform 116

Jun 07, 2018: Blood test may identify pregnant women at risk of premature birth 117

Jun 04, 2018: Diuretic as effective as antibiotics to treat women's acne 118

Apr 10, 2018: Global Genes Partners with University of Pennsylvania Orphan Disease Center for 2018 RARE Patient Advocacy Symposium 119

Appendix 120

Methodology 120

About GlobalData 120

Contact Us 120

Disclaimer 120


List of Figure

List of Figures

University of Pennsylvania, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

University of Pennsylvania, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

University of Pennsylvania, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

University of Pennsylvania, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

University of Pennsylvania, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8

University of Pennsylvania, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 9

University of Pennsylvania, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10

University of Pennsylvania, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 11

University of Pennsylvania, Medical Devices Deals, 2012 to YTD 2018 13


List of Table

List of Tables

University of Pennsylvania, Pharmaceuticals & Healthcare, Key Facts 2

University of Pennsylvania, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8

University of Pennsylvania, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 9

University of Pennsylvania, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10

University of Pennsylvania, Deals By Therapy Area, 2012 to YTD 2018 11

University of Pennsylvania, Medical Devices Deals, 2012 to YTD 2018 13

University of Pennsylvania, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 14

Carisma Therapeutics Raises USD53 Million in Series A Financing 18

Tmunity Therapeutics Raises Additional USD35 Million in Series A Venture Financing 20

Tmunity Therapeutics Raises USD100 Million in Series A Venture Financing 22

Amicus Therapeutics Enters into Research and Development Agreement with Perelman School of Medicine at the University of Pennsylvania 24

BioRestorative Therapies Enters into Research Agreement with University of Pennsylvania 25

Aevitas Therapeutics Enters into Research Agreement with University of Pennsylvania 26

Ophthotech and University of Pennsylvania Enter into Agreement 27

Johnson & Johnson Innovation and Janssen Pharma Enter into Research Partnership with University of Pennsylvania 28

JW Pharma Enters into Agreement with University of Pennsylvania 29

Incyte Enters into Research Agreement with Abramson Cancer Center 30

Tempus Health Enters into Agreement with Penn Medicine 31

Liquid Biotech Enters into Research Agreement with University of Pennsylvania 32

Celgene Enters into Co-Development Agreement with Abramson Cancer Center 33

Bluepen Biomarkers Enters into Agreement with University of Pennsylvania 34

Biogen Enters into Co-Development Agreement with University of Pennsylvania 35

Seres Therapeutics Enters into Agreement with University of Pennsylvania 36

Audentes Therapeutics Amends Co-Development with University of Pennsylvania 37

Genisphere Enters into Research Agreement with University of Pennsylvania 38

NeuroVive Pharma Enters into Research Agreement with University of Pennsylvania 39

Johnson & Johnson Consumer Enters into Research Agreement with University of Pennsylvania 40

Janssen Pharma Enters into Agreement with University of Pennsylvania 41

Lightlake Therapeutics Enters into Agreement with University of Pennsylvania 42

Epic Sciences Partners with Abramson Cancer Center 43

BioRestorative Therapies Enters into Research Agreement with University of Pennsylvania 44

PTC Therapeutics Enters into Agreement with University of Pennsylvania 45

CCFA Enters into Research Agreement with Penn Med and Nestle Health Science 46

Dimension Therapeutics Amends Research Agreement with University of Pennsylvania 47

Genzyme Enters into Co-Development Agreement with University of Florida and University of Pennsylvania 48

PolyMedix Enters Into Co-Development Agreement With University of Pennsylvania 49

Precision BioSciences Enters into Licensing Agreement with University of Pennsylvania 50

Ophthotech Enters into Licensing Agreement with University of Florida Research Foundation and the University of Pennsylvania 51

ImmunoRestoration Enters into Licensing Agreement with University of Pennsylvania 52

Arrakis Therapeutics Enters into Licensing Agreement with University of Pennsylvania 53

Expres2ion Biotech Enters into Licensing Agreement with University of Pennsylvania 54

Dimension Therapeutics Enters into Licensing Agreement with Perelman School of Medicine at the University of Pennsylvania 55

Kythera Biopharma Enters into Licensing Agreement with University of Pennsylvania 56

Spark Therapeutics Enters into Licensing Agreement with University of Pennsylvania for Proviral Plasmids 57

Regenxbio Enters into Licensing Agreement with University of Pennsylvania and University of Minnesota 58

Advaxis and University of Pennsylvania Restructure Their Exclusive License Agreement 59

Cetazam Therapeutics Enters into Licensing Agreement with Perelman School of Medicine 60

Amyndas Pharma Enters into Licensing Agreement with University of Pennsylvania 61

Spark Therapeutics Amends Licensing Agreement with University of Pennsylvania 62

Novartis Enters Into Licensing Agreement With University of Pennsylvania For All CARs 63

ImmunoCellular Therapeutics Enters Into Licensing Agreement With University of Pennsylvania For Dendritic-Cell Production Technology 65

Agios Pharma Enters Into Licensing Agreement With University of Pennsylvania 66

Tmunity Therapeutics Raises USD10 Million in Equity Financing 67

University Of Pennsylvania Sells Portion Of Royalty Interest In Juxtapid For USD 55 Million 68

University of Pennsylvania Health System To Acquire Chester County Hospital 69

University of Pennsylvania, Key Competitors 70

University of Pennsylvania, Key Employees 71

University of Pennsylvania, Subsidiaries 72

You can also purchase parts of this report.
Do you want to check out a section wise price list?
Get Price Break-up

Why Buy From US?

RRR
Refine Robust Result (RRR) Framework

What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story

reach
Our Reach Is Unmatched

We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.

Research
Shifting the Research Paradigm

While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.

Insite
More Insights-Better Decisions

With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.

Trust
Transparency and Trust

Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.

support
Round the Clock Support

If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.

Why Client Choose Us?

400000+ Reports in repository
150+ Consulting project a year
100+ Analysts
8000+ Client Queries in 2022